Abstracts tagged "T cells and systemic lupus erythematosus (SLE)"

Abstract Number: 148 • 2018 ACR/ARHP Annual Meeting
High Level of CD38 Expression in SLE CD8 T Cells Dictates Decreased Cytotoxicity
Eri Katsuyama, Abel Suarez-Fueyo, Sean Bradley, Michihito Kono, Lama Mulki, Vasileios C. Kyttaris and George C Tsokos, Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA
Background/Purpose: CD38 is an ectonucleotidase that has the ability to degrade nicotinamide adenine dinucleotide (NAD). The percentage of CD38 expressing CD8 T cells are increased…
Abstract Number: 972 • 2018 ACR/ARHP Annual Meeting
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Joan T. Merrill¹, Diane E. Shevell², Dominique Duchesne², Miroslawa Nowak², Sudeep Kundu², Ihab G. Girgis², Yanhua Sarah Hu², Steven G. Nadler³, Subhashis Banerjee² and John Throup², ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol-Myers Squibb, Princeton, NJ, ³Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The T cell costimulatory molecule, CD28, is critical for the activation of pathogenic T cells in autoimmune diseases.1,2 An anti-CD28 domain antagonist antibody, lulizumab…
Abstract Number: 973 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Combined with Rapamycin Efficiently Promoted Disease Remission and Recovered the Balance of Th17/Regulatory T Cells in Patients with Refractory Systemic Lupus Erythematosus
Xiaona Jing¹, Chong Gao², Liran Hao¹, Meihua Hao¹, Zhaoyun Liang¹, Xiao-Feng Li³ and Junwei Chen¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ³Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose:To observe the clinical effect of low-dose IL-2 combined with rapamycin on the balance of Th17/Treg cells and on remission of patients with refractory SLE.…
Abstract Number: 2947 • 2018 ACR/ARHP Annual Meeting
Peripheral Helper T Cells in Systemic Lupus Erythematosus
Ayako Makiyama^1,2, Asako Chiba¹, Goh Murayama³, Ken Yamaji³, Naoto Tamura³ and Sachiko Miyake¹, ¹Immunology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Autoreactive T-B cell interactions in lymphoid tissue have been thought to play a crucial role in the autoantibody production in systemic lupus erythematosus (SLE).…
Abstract Number: 2883 • 2016 ACR/ARHP Annual Meeting
The CD4+CD52low T Cell Contributes to the Development of Systemic Lupus Erythematosus through the CCR8/TARC Pathway
Tomohito Sato¹, Masataka Umeda¹, Tomohiro Koga², Takashi Igawa¹, Syota Kurushima¹, Ayuko Takatani¹, Toshimasa Shimizu¹, Shoichi Fukui¹, Ayako Nishino¹, Yoshiro Horai¹, Shinya Kawashiri¹, Naoki Iwamoto¹, Yasuko Hirai¹, Mami Tamai¹, Hideki Nakamura¹, Tomoki Origuchi³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ²Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki City, Japan
Background/Purpose: CD52 is a cell-surface glycoprotein that is widely expressed in lymphocytes, monocytes and eosinophils. CD4+CD52high T cells inhibit the activation of CD4+CD52low T cells…
Abstract Number: 813 • 2015 ACR/ARHP Annual Meeting
Expression of Inducible Costimulator Ligand (ICOSL) on CD4+ T Cells in Patients with Systemic Lupus Erythematosus
Minyoung Her¹, Dongyook Kim¹, JeongHa Park² and Donghoon Han³, ¹Department of Internal medicine, Division of Rheumatology, Inje university, Busan Paik hospital, Busan, South Korea, ²Wallas Memorial Baptist Hospital, Busan, South Korea, ³Inje university, Busan Paik hospital, Busan, South Korea
Background/Purpose: Inducible costimulator (ICOS) is an immunostimulatory receptor that belongs to the CD28/CTLA4 family. ICOSL (ICOS ligand), which belongs to the B7 family, is the…
Abstract Number: 1935 • 2015 ACR/ARHP Annual Meeting
Regulation of T Follicular Helper Cells in Systemic Lupus Erythematosus By E3 Ubiquitin Ligase Cbl-b
William Willis¹, Yun Xiao², Nicholas A. Young¹, Wael N. Jarjour¹ and Jian Zhang², ¹Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Activation of polyclonal CD4+ T cells and B cells is a hallmark of human and murine lupus, which suggests a global defect in the…
Abstract Number: 3019 • 2015 ACR/ARHP Annual Meeting
The CD4+CD52low T Cell Contributes to Disease Activity and Autoantybody Production in Systemic Lupus Erythematosus
Masataka Umeda¹, Tomohiro Koga¹, Kunihiro Ichinose², Toru Michitsuji¹, Toshimasa Shimizu², Shoichi Fukui³, Ayako Nishino³, Yoshikazu Nakashima⁴, Yoshiro Horai¹, Takahisa Suzuki¹, Shin-ya Kawashiri³, Naoki Iwamoto¹, Toshiyuki Aramaki⁵, Mami Tamai¹, Yasuko Hirai¹, Hideki Nakamura¹, Kazuo Yamamoto⁶, Tomoki Origuchi^7,8, Yukitaka Ueki⁹ and Atsushi Kawakami¹, ¹Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Rheumatology, Nagasaki University, Nagasaki, Japan, ⁵Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁶Biomedical Research Support Center, Nagasaki University School of Medicine, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁸Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: CD52 is a cell-surface glycoprotein that is widely expressed in lymphocytes, monocytes and eosinophils. The anti-CD52 antibody has been used to treat multiple autoimmune…
Abstract Number: 2680 • 2014 ACR/ARHP Annual Meeting
DNA Hydroxymethylation Changes in CD4+T Cells from Patients with Systemic Lupus Erythematosus
Ming Zhao, Wei Liao, Bochen Zhu, Ruifang Wu and Qianjin Lu, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose Recent studies have uncovered 5-hydroxymethylcytosine (5hmC) as the sixth base of the genome, and that the Ten-eleven translocation (TET) family proteins is responsible for…
Abstract Number: L8 • 2013 ACR/ARHP Annual Meeting
Overexpression of Set1 at the Promoter Contributes to cAMP Response Element Modulator Alpha Overexpression in Systemic Lupus Erythematosus
Qing Zhang¹, Huilin Zhang², Hai Long¹, Jieyue Liao³, Ming Zhao¹, Xiangning Qiu¹ and Qianjin Lu¹, ¹Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, ²Nursing Department, Second Xiangya Hospital, Central South University, Changsha, China, ³Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: In recent years, accumulating evidence has demonstrated that increased cAMP response element modulator α (CREMα) which contributes to IL-2 reduction and IL-17A overproduction in…
Abstract Number: 1743 • 2013 ACR/ARHP Annual Meeting
Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study
Barbara Sullivan¹, Wayne H. Tsuji², Vishala L. Chindalore³, Thomas D. Geppert⁴, Alla Rudinskaya⁵, Patricia Pardo⁶, Alan Kivitz⁷, C. Michael Neuwelt⁸, Meggan Mackay⁹, R. John Looney¹⁰, J. Carter Thorne¹¹, Marilee Andrew¹², Greg Arnold¹³, Michael Boedigheimer¹, Kit Chiu¹, Cherie Green¹, Arunan Kaliyaperumal¹, Christine Wang¹⁴, Andrew Welcher¹ and James Chung¹, ¹Amgen, Thousand Oaks, CA, ²Clinical Research/Inflammation, Amgen, Seattle, WA, ³Anniston Medical Clinic PC, Anniston, AL, ⁴Metroplex Clinical Research Center, LLC, Dallas, TX, ⁵Danbury Hospital, Danbury, CT, ⁶MRA Clinical Research, Miami, FL, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸East Bay Rheumatology Research Institute, San Leandro, CA, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Amgen, Seattle, WA, ¹³Medical Sciences, Amgen, Thousand Oaks, CA, ¹⁴Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: The interaction of inducible costimulator (ICOS) with its ligand, B7-related protein-1 (B7RP-1 or ICOSL), plays a role in T cell differentiation, cytokine production, and…
Abstract Number: 2497 • 2012 ACR/ARHP Annual Meeting
Altered Circulating Follicular Helper T Cell Phenotype and Subset Composition Are Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Hsi-en Ho¹, Jin Young Choi², Viviane M. Bunin², Sandra G. Pasoto³, Solange Carrasco⁴, Eduardo F. Borba⁵, Celio R. Goncalves⁶, Priscila R. Costa⁷, Esper G. Kallas⁷, Eloisa Bonfa⁶ and Joseph E. Craft², ¹Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, ³Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴University of São Paulo, São Paulo, Brazil, ⁵Rheumatology Division; University of São Paulo, São Paulo, Brazil, ⁶Universidade de São Paulo, Division of Rheumatology, Faculdade de Medicina, Sao Paulo, Brazil, ⁷Universidade de São Paulo, Division of Immunology, Faculdade de Medicina, Sao Paulo, Brazil
Background/Purpose: Autoreactive B cells in SLE undergo autoantigen selection, suggesting a requirement for germinal center follicular helper T (Tfh) cells in their maturation. However, evidence…
Abstract Number: 2499 • 2012 ACR/ARHP Annual Meeting
The Peroxisome-Proliferator Activated Receptor-γ Agonist Pioglitazone Modulates Aberrant T-Cell Responses in Systemic Lupus Erythematosus
Wenpu Zhao¹, Celine C. Berthier², Matthias Kretzler³ and Mariana J. Kaplan⁴, ¹University of Michigan Rheumatology, Ann Arbor, MI, ²Nephrology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ⁴Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Previous studies indicate that PPAR-γ agonists, including pioglitazone (PIO), down-regulate autoimmune responses and renal inflammation in murine SLE. However, the mechanisms implicated in this process…
Abstract Number: 2337 • 2012 ACR/ARHP Annual Meeting
Therapeutic Promotion of CD8 CTL by CpG Oligodeoxynucleotides (ODN) in an Induced Model of Lupus
Maksym Puliaiev¹, Kateryna Soloviova¹ and Charles S. Via², ¹Pathology Department, Uniformed Services University of Health Sciences, Bethesda, MD, ²Pathology Rm B3-100, Uniformed Services University of Health Sciences, Bethesda, MD
Background/Purpose: In addition to TcR signaling and costimulation, CD8 T cells require a third signal to mature into effector cytotoxic T lymphocytes (CTL). In pathogen…
Abstract Number: 2316 • 2012 ACR/ARHP Annual Meeting
Generation of CD4⁺ Follicular Helper Tcells by Complement and Immune Complexes
Anil K. Chauhan¹, Richard DiPaolo² and Terry L. Moore³, ¹Rheumatology, Saint Louis University, St. Louis, MO, ²Molecular Microbiology and Immunology, Saint Louis, MO, ³Internal Medicine/Rheumatology, Saint Louis University, Saint Louis, MO
Background/Purpose: Complement opsonized immune complexes (ICs) are key players of disease pathology. We showed in systemic lupus erythematosus (SLE), ICs and complement (C’) drive activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].